Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)
Clinical trial NCT03448835 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03448835
- Sponsor
- The Netherlands Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-07
- Primary completion
- 2026-10-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.